Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.

Saved in:
Bibliographic Details
Title: Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.
Authors: Marsh R; Department of Applied Sciences, Northumbria University, Newcastle, UK., Santos CD; Department of Natural Sciences, Manchester Metropolitan University, UK., Yule A; School of Medicine, University of Nottingham, UK; NIHR Nottingham Biomedical Research Centre, UK., Dellschaft NS; Sir Peter Mansfield Imaging Centre, University of Nottingham, UK., Hoad CL; Sir Peter Mansfield Imaging Centre, University of Nottingham, UK., Ng C; School of Medicine, University of Nottingham, UK; NIHR Nottingham Biomedical Research Centre, UK., Major G; School of Medicine, University of Nottingham, UK; Nestlé Institute of Health Sciences, Société des Produits Nestlé, Lausanne, Switzerland., Smyth AR; School of Medicine, University of Nottingham, UK; NIHR Nottingham Biomedical Research Centre, UK; School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK., Rivett D; Department of Natural Sciences, Manchester Metropolitan University, UK., van der Gast C; Department of Applied Sciences, Northumbria University, Newcastle, UK; Department of Respiratory Medicine, Northern Care Alliance NHS Foundation Trust, Salford, UK. Electronic address: chris.vandergast@northumbria.ac.uk.
Source: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society [J Cyst Fibros] 2024 Sep; Vol. 23 (5), pp. 967-976. Date of Electronic Publication: 2024 May 14.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101128966 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5010 (Electronic) Linking ISSN: 15691993 NLM ISO Abbreviation: J Cyst Fibros Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-5010
DOI:10.1016/j.jcf.2024.05.002